Concepedia

Johnny Nagasawa

JN

Statistics

Publications

13

Citations

1.2K

H-Index

12

Active since

2004

Affiliations

Edison Pharmaceuticals (United States)(Current)

General Atomics (United States)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Johnny Nagasawa is an author at Edison Pharmaceuticals (United States) specializing in pharmacology, drug discovery, and medicinal chemistry.

Publications per year

2004–2018

13

Publications

13

Discovery and SAR of 5-(3-Chlorophenylamino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer

Fabrice Pierre, Peter Chua, Sean O’Brien et al. · Journal of Medicinal Chemistry · 2010 · 299 citations · Full text

, , +15

Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts

Andiliy Lai, Mehmet Kahraman, Steven P. Govek et al. · Journal of Medicinal Chemistry · 2015 · 247 citations · Full text

, , +13

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics

Mustapha Haddach, Michael K. Schwaebe, Jerome Michaux et al. · ACS Medicinal Chemistry Letters · 2012 · 164 citations

, , +14

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer

Fabrice Pierre, Peter Chua, Sean O’Brien et al. · Molecular and Cellular Biochemistry · 2011 · 155 citations

, , +4

The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer

James D. Joseph, Beatrice Darimont, Wei Zhou et al. · eLife · 2016 · 119 citations · Full text

, , +15

1–5 of 13